No profile data available.
Alnylam Pharmaceuticals, Inc. (ALNY) is a healthcare company in the additional hormone and metabolic drugs industry, based in Cambridge, United States, with about 2,500 full-time employees.
It reported revenue of $3.71 billion for fiscal year 2025, up 65.2% from fiscal year 2024, and net income of $313.75 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $1.29 billion. United States was its largest region in fiscal year 2025, with 69% of revenue. Its market capitalization was $31.13 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally.
Alnylam Pharmaceuticals reported $3.71 billion in revenue for fiscal year 2025, up 65.2% from $2.25 billion in fiscal year 2024. In Q2 2026 revenue was $1.29 billion.
United States: 69% of revenue by region in fiscal year 2025, followed by Europe (22%).
$31.13 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (additional hormone and metabolic drugs) include Corcept Therapeutics Incorporated (CORT), BridgeBio Pharma, Inc. (BBIO), Amylyx Pharmaceuticals, Inc. (AMLX), MBX Biosciences, Inc. (MBX).